NCT03129594

Brief Summary

GLP-1(9-36) amide and (9-37), which was previously thought to be the inactive metabolite of GLP-1, also exerts cardioprotective effects. Direct administration of GLP-1(9-36) during reperfusion reduced ischaemic damage in isolated hearts and increased cGMP release, vasodilatation and coronary flow in AMI mouse model, one may speculate that total GLP-1 level may associate with adverse cardiovascular events in AMI patients, the hypothesis is therefore tested in this study.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
709

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Feb 2013

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2013

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2015

Completed
2.2 years until next milestone

First Submitted

Initial submission to the registry

April 23, 2017

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 26, 2017

Completed
Last Updated

October 4, 2017

Status Verified

October 1, 2017

Enrollment Period

2 years

First QC Date

April 23, 2017

Last Update Submit

October 3, 2017

Conditions

Coronary AngiographyGlucagon-like Peptide-1

Outcome Measures

Primary Outcomes (2)

  • all-cause mortality

    The median follow-up was 29 months

  • cardiovascular mortality

    The median follow-up was 29 months

Secondary Outcomes (5)

  • non-cardiovascular mortality

    The median follow-up was 29 months

  • Myocardial infarction

    The median follow-up was 29 months

  • heart failure readmission

    The median follow-up was 29 months

  • Stroke

    The median follow-up was 29 months

  • repeated revascularization

    The median follow-up was 29 months

Interventions

plasma glucagon-like peptide-1 levelsDIAGNOSTIC_TEST

The plasma GLP-1 levels was determined by enzymatic assays.

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

A single center study on PCI-treated myocardial infarction patients

You may qualify if:

  • consecutive patients of acute AMI come to our department,absent of cardiogenic shock, and survival for at least 24 h after PCI treatment.

You may not qualify if:

  • patients with cancer, and patients who were taking a DPP4 inhibitor or a glucagon-like peptide-1 (GLP-1) analogue

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor

Study Record Dates

First Submitted

April 23, 2017

First Posted

April 26, 2017

Study Start

February 1, 2013

Primary Completion

February 1, 2015

Study Completion

February 1, 2015

Last Updated

October 4, 2017

Record last verified: 2017-10